KR101869144B1 - 포스포디에스테라아제 10 억제제(pde-10)로서 신규 피리미딘 유도체 - Google Patents

포스포디에스테라아제 10 억제제(pde-10)로서 신규 피리미딘 유도체 Download PDF

Info

Publication number
KR101869144B1
KR101869144B1 KR1020157022767A KR20157022767A KR101869144B1 KR 101869144 B1 KR101869144 B1 KR 101869144B1 KR 1020157022767 A KR1020157022767 A KR 1020157022767A KR 20157022767 A KR20157022767 A KR 20157022767A KR 101869144 B1 KR101869144 B1 KR 101869144B1
Authority
KR
South Korea
Prior art keywords
bromo
pyrimidine
diamine
group
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157022767A
Other languages
English (en)
Korean (ko)
Other versions
KR20150126601A (ko
Inventor
주안 카마초 고메즈
줄리오 카스트로 팔로미노 라리아
Original Assignee
팔로바이오파마, 에스.엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 팔로바이오파마, 에스.엘. filed Critical 팔로바이오파마, 에스.엘.
Publication of KR20150126601A publication Critical patent/KR20150126601A/ko
Application granted granted Critical
Publication of KR101869144B1 publication Critical patent/KR101869144B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020157022767A 2013-01-24 2014-01-23 포스포디에스테라아제 10 억제제(pde-10)로서 신규 피리미딘 유도체 Active KR101869144B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201330082 2013-01-24
ES201330082A ES2480341B1 (es) 2013-01-24 2013-01-24 Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
PCT/EP2014/051290 WO2014114695A1 (en) 2013-01-24 2014-01-23 New pyrimidine derivatives as phosphodiesterase 10 inhibitors (pde-10)

Publications (2)

Publication Number Publication Date
KR20150126601A KR20150126601A (ko) 2015-11-12
KR101869144B1 true KR101869144B1 (ko) 2018-07-19

Family

ID=50071592

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157022767A Active KR101869144B1 (ko) 2013-01-24 2014-01-23 포스포디에스테라아제 10 억제제(pde-10)로서 신규 피리미딘 유도체

Country Status (23)

Country Link
US (1) US9447095B2 (https=)
EP (1) EP2948443B1 (https=)
JP (1) JP6254194B2 (https=)
KR (1) KR101869144B1 (https=)
CN (1) CN105008346B (https=)
AU (1) AU2014209950B2 (https=)
BR (1) BR112015017678B1 (https=)
CA (1) CA2897260C (https=)
CY (1) CY1118552T1 (https=)
DK (1) DK2948443T3 (https=)
EA (1) EA026330B1 (https=)
ES (2) ES2480341B1 (https=)
HR (1) HRP20161495T1 (https=)
HU (1) HUE031831T2 (https=)
LT (1) LT2948443T (https=)
ME (1) ME02551B (https=)
MX (1) MX361160B (https=)
PL (1) PL2948443T3 (https=)
PT (1) PT2948443T (https=)
RS (1) RS55449B1 (https=)
SI (1) SI2948443T1 (https=)
SM (1) SMT201600428B (https=)
WO (1) WO2014114695A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
CN107286146B (zh) * 2017-07-05 2020-07-31 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途
CN116836162B (zh) * 2023-05-24 2025-09-05 南方医科大学 吡唑[4,3-c]吡啶类化合物或其药学上可接受的盐及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011121418A1 (en) * 2010-03-31 2011-10-06 Palobiofarma, S.L. 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110891A2 (en) * 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
CN105125547A (zh) 2009-05-07 2015-12-09 费瑞姆医药有限公司 苯氧基甲基杂环化合物
EP2434885B1 (en) 2009-05-27 2014-03-26 Merck Sharp & Dohme Corp. Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors
JP6007102B2 (ja) 2009-06-24 2016-10-12 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 画像情報に基づいた構造の輪郭の決定
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
US8592423B2 (en) 2011-06-21 2013-11-26 Bristol-Myers Squibb Company Inhibitors of PDE10
AU2012318874A1 (en) * 2011-10-06 2014-05-15 Merck Sharp & Dohme Corp. 1,3-substituted azetidine PDE10 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011121418A1 (en) * 2010-03-31 2011-10-06 Palobiofarma, S.L. 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
KR20130028732A (ko) * 2010-03-31 2013-03-19 팔로바이오파마, 에스.엘. 4―아미노피리미딘 유도체 및 아데노신 ａ2ａ 수용체 안타고니스트로서의 이들의 용도

Also Published As

Publication number Publication date
RS55449B1 (sr) 2017-04-28
WO2014114695A1 (en) 2014-07-31
DK2948443T3 (en) 2016-12-12
US9447095B2 (en) 2016-09-20
PT2948443T (pt) 2016-11-15
US20150336953A1 (en) 2015-11-26
AU2014209950A1 (en) 2015-08-27
EA026330B1 (ru) 2017-03-31
LT2948443T (lt) 2016-12-12
ES2480341A1 (es) 2014-07-25
PL2948443T3 (pl) 2017-02-28
CA2897260C (en) 2018-11-20
HRP20161495T1 (hr) 2016-12-16
CN105008346B (zh) 2018-11-13
ME02551B (me) 2017-02-20
BR112015017678B1 (pt) 2023-02-14
AU2014209950B2 (en) 2017-04-20
KR20150126601A (ko) 2015-11-12
BR112015017678A2 (pt) 2017-07-11
CA2897260A1 (en) 2014-07-31
EP2948443A1 (en) 2015-12-02
SI2948443T1 (sl) 2016-12-30
CN105008346A (zh) 2015-10-28
JP2016505059A (ja) 2016-02-18
JP6254194B2 (ja) 2017-12-27
EP2948443B1 (en) 2016-08-31
MX361160B (es) 2018-11-28
ES2480341B1 (es) 2015-01-22
SMT201600428B (it) 2017-01-10
MX2015009627A (es) 2016-04-25
ES2611170T3 (es) 2017-05-05
HUE031831T2 (en) 2017-08-28
CY1118552T1 (el) 2017-07-12
EA201591369A1 (ru) 2016-01-29

Similar Documents

Publication Publication Date Title
US10766897B2 (en) Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors
EP3356345B1 (en) Heteroaryl derivatives as sepiapterin reductase inhibitors
US20120088753A1 (en) Pyrrolopyrimidines and used as kinase inhibitors
US11319303B2 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
JP2009529541A (ja) 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
WO2013139882A1 (en) Pyrazolopyridines for treatment of parkinsons disease
MX2013006054A (es) Compuestos de triazolopiridina.
US20150258101A1 (en) New compounds
CA3003559A1 (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
US10278973B2 (en) Hydroxyl purine compounds and use thereof
KR101869144B1 (ko) 포스포디에스테라아제 10 억제제(pde-10)로서 신규 피리미딘 유도체
US20140288043A1 (en) Pyrazolopyridine compounds
WO2025061177A1 (zh) 一种治疗cgrp相关障碍的小分子药物
BRPI0719333B1 (pt) Imidazotriazinas e imidazopirimidinas como inibidores de cinase, composição farmacêutica que as compreende e métodos in vitro

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150821

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161109

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180220

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20180528

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180612

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180612

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20210527

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20210527

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20220527

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20220527

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230525

Start annual number: 6

End annual number: 6